|
|
| | Pamidronate disodium salt Basic information |
| | Pamidronate disodium salt Chemical Properties |
| Melting point | 300 °C | | storage temp. | 2-8°C | | solubility | H2O: 28 mg/mL | | form | solid | | color | white | | Water Solubility | H2O: 28mg/mL | | Merck | 14,7003 | | Stability: | Hygroscopic | | InChI | 1S/C3H11NO7P2.2Na.H2O/c4-2-1-3(5,12(6,7)8)13(9,10)11;;;/h5H,1-2,4H2,(H2,6,7,8)(H2,9,10,11);;;1H2/q;2*+1;/p-2 | | InChIKey | TVQNUQCYOOJTMK-UHFFFAOYSA-L | | SMILES | O.[Na+].[Na+].NCCC(O)(P(O)([O-])=O)P(O)([O-])=O | | CAS DataBase Reference | 57248-88-1(CAS DataBase Reference) |
| Hazard Codes | Xn | | Risk Statements | 22-48-41-37/38-20/21/22 | | Safety Statements | 22-26-36/37/39-45 | | RIDADR | 3077 | | WGK Germany | 3 | | RTECS | SZ6525000 | | HazardClass | IRRITANT | | HS Code | 29319090 | | Storage Class | 11 - Combustible Solids | | Hazard Classifications | Acute Tox. 4 Oral |
| | Pamidronate disodium salt Usage And Synthesis |
| Description | Disodium pamidronate is a calcium metabolism regulator useful in the treatment of
hypercalcemia associated with malignancy. It presumably reduces the bone resorption of
calcium by inhibiting the formation and attachment of osteoclasts. Other potential uses
include osteoporosis and calcitonin-resistant Paget’s disease. | | Chemical Properties | White Crystals | | Originator | Henkel (United Kingdom) | | Uses | A bisphosphonate antiresorptive agent; bone resorption inhibitor. | | Uses | Pamidronate disodium is a nitrogen containing bisphosphonate, used to prevent osteoporosis. It is used to prevent bone loss, and treat osteoporosis. | | Uses | A farnesyl diphosphate synthase inhibitor | | Manufacturing Process | For a batch size of 5 L, 587.5 g (3.2 moles) of mannitol is dissolved in 3.5 L of water. Pamidronic acid (31.6 g, 0.133 moles) is mixed with a 1.0 L aliquot of the mannitol solution to form a slurry. The slurry is then transferred into the remainder of the mannitol solution, and stirred for at least 15 min. Aqueous 1 N sodium hydroxide (270 ml) is then added and the mixture is stirred until a clear, colorless solution results. The pH is then adjusted to 6.50.1 using either 1 M aqueous phosphoric acid or 1 N aqueous sodium hydroxide, as needed. The solution is then filtered through a 0.22 micron filter, and filled at 20°C into vials at 4.0 ml (4.172 g)/vial, under sterile conditions. The aqueous solution is frozen at -37°C and lyophilized (20 mbar, 20°-40°C) to yield 1,250 vials, each containing 30 mg of amorphous disodium pamidronate. The vials are sealed under positive nitrogen pressure. The disodium pamidronate is amorphous (noncrystalline) by X-ray diffraction and contains 0.7 wt-% water. | | Brand name | Aredia (Novartis). | | Therapeutic Function | Bone resorption suppressant | | Biochem/physiol Actions | Pamidronate disodiumhas the ability to block Wnt and β-catenin signaling, which modulates the osteogenic differentiation in bone marrow mesenchymal stem cells (BMMSCs). It can also reduce bilirubin-impaired apoptosis and helps to develop dentinogenic dysfunction of stem cells from human deciduous teeth. | | Veterinary Drugs and Treatments | Pamidronate may be useful in treating hypercalcemia associated
with vitamin D-related toxicoses or hypercalcemia of malignancy.
There is ongoing research on the use of this drug to determine if
it has clinical usefulness in directly treating “micro-metastases” in
osteosarcomas. |
| | Pamidronate disodium salt Preparation Products And Raw materials |
|